Product How it works Pricing Blog FAQ About Contact
SAB Biotherapeutics

SAB Biotherapeutics (NASDAQ: SABS) net income

SAB Biotherapeutics reported a net profit of $13.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $34.1m. Earnings per share were $0.22.

SAB Biotherapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 4 of those 6 years.

Net income, in millions of US dollars20.12020-17.12021-18.72022-42.22023-34.1202413.32025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025$13.3m——$0.22
2024−$34.1m—−2,579.0%−$3.68
2023−$42.2m—−1,884.5%−$7.64
2022−$18.7m—−78.4%−$0.43
2021−$17.1m−185.2%−28.2%−$0.63
2020$20.1m—36.4%$0.79

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

SAB Biotherapeutics net income compared with its sector

By net income for its latest fiscal year, SAB Biotherapeutics ranks 157th of the 501 US health care companies with a page on Celsmar.

RankCompanyNet incomeNet margin
155thLifeMD$14.4m7.4%
156thPro-DEX$13.7m17.6%
157thSAB Biotherapeutics$13.3m—
158thNRC Health$11.6m8.4%
159thElectromed$11.3m15.3%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of SAB Biotherapeutics

How much did SAB Biotherapeutics earn in fiscal 2025?
SAB Biotherapeutics reported a net profit of $13.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $34.1m.
What are the earnings per share of SAB Biotherapeutics?
They were $0.22 in fiscal 2025, compared with −$3.68 in fiscal 2024.
What was the most profitable year for SAB Biotherapeutics?
Of its last 6 fiscal years, fiscal 2020, with $20.1m.
Where does SAB Biotherapeutics rank in its sector by net income?
It ranks 157th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for SAB Biotherapeutics come from?
From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on SAB Biotherapeutics: the SAB Biotherapeutics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.